3D Bioprinted Scar Tissue Model Using Silk Fibroin Bioink
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying scar tissue pathophysiology and drug testing are limited by the lack of a suitable in vitro model that can replicate the 3D structure and cellular alignment of scar tissue, leading to inadequate understanding and ineffective scar resolution strategies.
Innovation Solution
A 3D bioprinted scar tissue model is created using a bioink composition comprising silk fibroin protein, collagen, IL-6, IL-8, and TGF-β1, along with tissue-specific fibroblastic cells, which replicates the parallel ECM alignment and gene expression patterns of natural scar tissue through layer-by-layer bioprinting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional 2D cell culture methods are used, then the simplicity of the model is maintained, but the ability to replicate 3D scar tissue structure and cellular alignment is insufficient
Solution Approach 1:
The patent transitions from traditional 2D cell culture to 3D bioprinting, adding a spatial dimension to replicate the actual architecture of scar tissue. The bioprinting process deposits bioink containing fibroblastic cells in a layer-by-layer manner to create a three-dimensional construct that mimics the 3D extracellular matrix organization and cellular alignment found in natural scar tissue, thereby resolving the contradiction between model simplicity and structural accuracy.
Solution Approach 2:
The patent uses a composite bioink formulation combining silk fibroin protein, collagen, and cytokines (IL-6, IL-8, TGF-β1) to create a multifunctional material that provides both structural support and biological signaling. This composite approach allows the model to simultaneously achieve structural fidelity, cellular functionality, and disease-relevant phenotypes while maintaining a unified material system rather than requiring multiple separate components.
2Reliability
If simple in vitro models are used, then the ease of operation is maintained, but the understanding of scar pathophysiology is limited
Solution Approach 1:
The patent incorporates cytokines (IL-6, IL-8, TGF-β1) directly into the bioink formulation before bioprinting, performing the differentiation-inducing action in advance during the printing process itself. This preliminary incorporation of bioactive molecules eliminates the need for subsequent complex treatment protocols and allows the fibroblastic cells to differentiate into myofibroblasts and produce scar-like ECM directly within the printed construct, thereby achieving high physiological relevance without increasing operational complexity.
Solution Approach 2:
The bioprinted scar tissue model is designed to self-organize and self-differentiate through the inherent properties of the bioink composition. The silk fibroin-collagen matrix and embedded cytokines create a self-sustaining system where fibroblastic cells automatically differentiate into myofibroblasts and produce scar-like extracellular matrix without requiring external intervention or complex culture conditions, thus achieving high reliability while maintaining ease of operation.
3Productivity
If rapid drug testing is not enabled, then the suitability for pharmaceutical research is insufficient, but the development of scar resolution strategies continues slowly
Solution Approach 1:
The patent creates a simplified copy or analogue of natural scar tissue through bioprinting, using bioink containing fibroblastic cells, silk fibroin, collagen, and cytokines to replicate the essential features of scar pathophysiology in a controlled in vitro system. This copied model maintains the key pathological characteristics (myofibroblast differentiation, excessive ECM synthesis, wound contraction) while being amenable to rapid drug screening, thereby enabling high-throughput pharmaceutical research without sacrificing physiological relevance.
Data Source
Figure 1~2
Figure 3A~3G
Figure 4A~4E
AI summary
The present disclosure relates to a bioink composition and a 3D bioprinted scar tissue model comprising the bioink composition, which closely replicates the physiological and architectural characteristics of naturally occurring scar tissue. The 3D bioprinted scar tissue can be used to test scar resolution treatments among others. The disclosure also relates to the method of fabricating the 3D bioprinted scar tissue along with an apparatus for bioprinting the 3D bioprinted scar tissue.